Callan Family Office’s AB InBev BUD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$7.3M Sell
105,167
-2,170
-2% -$157K 0.17% 125
2025
Q4
$6.87M Buy
107,337
+20,549
+24% +$1.28M 0.15% 138
2025
Q3
$5.17M Sell
86,788
-6,738
-7% -$424K 0.16% 142
2025
Q2
$6.43M Buy
93,526
+66,413
+245% +$4.46M 0.2% 121
2025
Q1
$1.67M Sell
27,113
-788
-3% -$43.1K 0.13% 147
2024
Q4
$1.4M Buy
+27,901
New +$1.61M 0.09% 191
2023
Q2
Sell
-10,200
Closed -$681K 116
2023
Q1
$681K Buy
+10,200
New +$616K 0.17% 77

Other funds holding BUD

Callan Family Office's BUD Position: Q1 2026 in Review

Callan Family Office reduced its AB InBev (BUD) stake by 2% in Q1 2026, selling an estimated $157K and leaving 105,167 shares worth $7.3M. The position accounts for 0.17% of the portfolio, ranked #125.

Callan Family Office first reported a position in BUD in Q1 2023 and has held it in 7 quarters since. 544 funds tracked by Wall St. Rank hold BUD as of Q1 2026.

  • Callan Family Office held 105,167 shares of AB InBev worth $7.3M as of Q1 2026.
  • Callan Family Office sold 2,170 AB InBev shares in Q1 2026, an estimated $157K.
  • AB InBev made up 0.17% of Callan Family Office's portfolio in Q1 2026, its #125 holding.
  • Callan Family Office first reported a position in AB InBev in Q1 2023 and has held it in 7 quarters since.
  • 544 funds tracked by Wall St. Rank held AB InBev as of Q1 2026.

Based on Callan Family Office's 13F filing for Q1 2026, filed 13 May 2026.